Evidence map›Paper›PMID 32072624›Full record

ArticleBritish journal of haematology2020

Variation in the Human Leukocyte Antigen system and risk for endemic Burkitt lymphoma in northern Uganda.

Samuel Kirimunda, Murielle Verboom, Isaac Otim, Mark Ssennono, Ismail D Legason, Hadijah Nabalende, Martin D Ogwang, Patrick Kerchan, Tobias Kinyera, Ivan Mwebaza and 11 more

Open access · greenAbstract read
In one paragraph

Article in British journal of haematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 2 countries.

Samuel KirimundaCollege of Health Sciences, Makerere University, Kampala, Uganda.
Murielle VerboomInstitute of Transfusion Medicine, Hannover, Germany.
Isaac OtimEMBLEM Study, St. Mary's Hospital, Lacor, Gulu & African Field Epidemiology Network, Kampala, Uganda.
Mark SsennonoEMBLEM Study, St. Mary's Hospital, Lacor, Gulu & African Field Epidemiology Network, Kampala, Uganda.
Ismail D LegasonEMBLEM Study, Kuluva Hospital, Kuluva, Arua & African Field Epidemiology Network, Kampala, Uganda.
Hadijah NabalendeEMBLEM Study, St. Mary's Hospital, Lacor, Gulu & African Field Epidemiology Network, Kampala, Uganda.
Martin D OgwangEMBLEM Study, St. Mary's Hospital, Lacor, Gulu & African Field Epidemiology Network, Kampala, Uganda.
Patrick KerchanEMBLEM Study, Kuluva Hospital, Kuluva, Arua & African Field Epidemiology Network, Kampala, Uganda.
Tobias KinyeraEMBLEM Study, St. Mary's Hospital, Lacor, Gulu & African Field Epidemiology Network, Kampala, Uganda.
Ivan MwebazaCollege of Health Sciences, Makerere University, Kampala, Uganda.
Moses JolobaCollege of Health Sciences, Makerere University, Kampala, Uganda.
Leona W AyersDepartment of Pathology, The Ohio State University, Columbus, OH, USA.
Steven J ReynoldsDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Kishor BhatiaInfections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Olusegun O OnabajoLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Michael HallenslebenInstitute of Transfusion Medicine, Hannover, Germany.
Robert J BiggarInfections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Ludmila Prokunina-OlssonLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
James J GoedertInfections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Rainer BlasczykInstitute of Transfusion Medicine, Hannover, Germany.
Sam M MbulaiteyeInfections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-8273-9831
National Institutes of Health · USSt. Mary's Hospital Lacor · UGInstitute for Transfusion Medicine · USKuluva Hospital · UGMakerere University · UGThe Ohio State University · US

Funding

International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZIAAI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REYNOLDS, STEVEN · 2009 to 2025
$23.5M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Infections, immunity, and inflammation in cancerZ01CP010150 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ENGELS, ERIC A · 2000 to 2008
$3.0M
CAPILLARY OPTICS TO CONTROL NEUTRONS FOR BNCTR43CA062702 · NCI · X-RAY OPTICAL SYSTEMS, INC. · PI XIAO, QI-FAN · 1994 to 1994
–
HHSIntramural NIH HHS Z01 CP010150Intramural Research ProgramNational Cancer Institute for African Scientists grant adminstered by US Civilian Research and Development Foundation (CRDF) Global DAA3-16-62702National Institute of Allergy and Infectious Diseases (SJR)NIH HHS
6 · The paper itself

Abstract

Endemic Burkitt lymphoma (eBL) is an aggressive childhood B-cell lymphoma associated with Plasmodium falciparum (Pf) malaria and Epstein-Barr virus (EBV) infections. Variation in the Human Leukocyte Antigen (HLA) system is suspected to play a role, but assessments using less accurate serology-based HLA typing techniques in small studies yielded conflicting results. We studied 200 eBL cases and 400 controls aged 0-15 years enrolled in northern Uganda and typed by accurate high-resolution HLA sequencing methods. HLA results were analyzed at one- or two-field resolution. Odds ratios and 95% confidence intervals (aOR, 95% CI) for eBL risk associated with common HLA alleles versus alleles that were rare (<1%) or differed by <2% between the cases and controls as the reference category, were estimated using multiple logistic regression adjusting for age, sex, microgeography, region, malaria positivity and treatment history, and genetic variants associated with eBL. Compared to the controls, eBL cases had a lower frequency of HLA-A*02 (aOR = 0·59, 95% CI 0·38-0·91), HLA-B*41 (aOR = 0·36, 95% CI 0·13-1·00), and HLA-B*58 alleles (aOR = 0·59, 95% CI 0·36-0·97). eBL cases had a lower frequency of HLA-DPB1 homozygosity (aOR = 0·57, 95% CI 0·40-0·82) but a higher frequency of HLA-DQA1 homozygosity (aOR = 2·19, 95% CI 1·42-3·37). Our results suggest that variation in HLA may be associated with eBL risk.

Indexed as

AdolescentBurkitt LymphomaChildChild, PreschoolFemaleHLA AntigensHumansInfantInfant, NewbornMaleRisk FactorsUgandaHLA AntigensBurkitt lymphomaepidemiologyEpstein-Barr virushuman leukocyte antigennon-Hodgkin lymphomaPlasmodium falciparum malaria

Identifiers

PMID32072624
PMCPMC7192769
OpenAlexW3007558601

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.